Filing Flows › Comparisons › CTSO vs IDXG
Cytosorbents vs Interpace Biosciences: CTSO and IDXG compared
Cytosorbents is the larger company: $9.6M of revenue in its latest quarter (Q2 2026) against $9.1M for Interpace Biosciences (Q2 2026). Cytosorbents is growing faster (+0.2% against -1% a year earlier). Interpace Biosciences is more profitable, with an operating margin of 3.5% against -27.4%.
Where the money goes: CTSO and IDXG
Cytosorbents (CTSO) · Q2 2026
Cytosorbents, Q2 2026: revenue $9.6M (+0.2% year over year), operating margin -27.4%, net loss $4.4M, operating cash flow −$583K. The chart follows the revenue to costs, profit and cash.
Interpace Biosciences (IDXG) · Q2 2026
Interpace Biosciences, Q2 2026: revenue $9.1M (-1% year over year), operating margin 3.5%, net earnings $158K, operating cash flow $98K. The chart follows the revenue to costs, profit and cash.
| Cytosorbents (CTSO) | Interpace Biosciences (IDXG) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $9.6M | $9.1M |
| Revenue growth, Y/Y | +0.2% | -1% |
| Gross margin | — | 61.9% |
| Operating margin | -27.4% | 3.5% |
| Net earnings | −$4.4M | $158K |
| Net margin | -45.9% | 1.7% |
| Operating cash flow | −$583K | $98K |
| Free cash flow | — | $41K |
Questions
Which is bigger, Cytosorbents or Interpace Biosciences?
Cytosorbents is the larger company: $9.6M of revenue in its latest quarter (Q2 2026) against $9.1M for Interpace Biosciences (Q2 2026).
Is Cytosorbents or Interpace Biosciences growing faster?
Cytosorbents is growing faster (+0.2% against -1% a year earlier).
Which is more profitable, Cytosorbents or Interpace Biosciences?
Interpace Biosciences is more profitable, with an operating margin of 3.5% against -27.4%.
More: Cytosorbents earnings · how Cytosorbents makes money · Interpace Biosciences earnings · how Interpace Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-Q filed Aug 10, 2026). Fiscal quarters can end on different dates. Not investment advice.